

**IMMUNOLOGICAL ASPECT IN  
COAGULATION DISORDERS  
( ESSAY )**

**THESIS**

Submitted for Partial Fulfilment  
of Master Degree in  
**PEDIATRICS**

By

**EBTISAM MOHAMED MAHMOUD ABD ALLA**  
M. B., B. Ch.

Supervised by

**Professor Dr. OMAR HELMY**

Professor and Head of Pediatric Department

**Professor Dr. FOUAD BADRAWY**

Professor of Pediatrics

Faculty of Medicine

Ain Shams University

**1984**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

" قالوا سبحانك لا علم لنا الا ما علمتنا

انك انت العليم الحكيم "

صدق الله العظيم

سورة البقرة : آية ٣٢



## ACKNOWLEDGEMENT

-----

I wish to express my deep thanks and gratitude to professor Dr. Omar Helmy, Professor of pediatrics, Faculty of Medicine, Ain Shams University, for giving me the privilege of working under his supervision, for his encouragement, <sup>a</sup>patience and unfailing guidance throughout the whole work.

I also express my thanks and gratitude to professor Dr. Fouad Badrawy, Assistant professor of pediatrics, Faculty of Medicine, Ain Shams University, for his continuous encouragement, valuable supervision and great cooperation throughout the whole work.

To everyone who participated in some way or another, to let this work come to such a final picture, I owe my thanks and gratitude.

- F.D. P = Fibrin degradation products.
- PTT = Partial thromboplastin time.
- VIII:C = Antihemophilic factor procoagulant activity
- TGT = Thromboplastin generation test.
- AIDS = Acquired immune deficiency syndrome
- FFP = Fresh frozen plasma.
- Cryo. = cryoprecipitate
- DDAVP = 1-deamino 8-D- arginine vasopressin
- FEIBA = Factor VIII inhibitor by passing activity
- APCCS = Activated prothrombin- complex concentrates
- DIC = Disseminated intravascular coagulation.
- PA. IgM= platelet associated IgM.
- PA.IgG = platelet associated IgG.
- ITP = Idiopathic thrombocytopenic purpura.
- VIII:R: Ag= Factor VIII related antigen
- HMW kininogen = High molecular weight kininogen.

# C O N T E N T S

|                                                         | Page |
|---------------------------------------------------------|------|
| - Introduction .....                                    | 1    |
| - Aim of the work.....                                  | 2    |
| - Blood coagulation.....                                | 3    |
| - The immune system.....                                | 13   |
| - Classification of coagulation disorders.....          | 21   |
| - Congenital plasma factor deficiencies.....            | 22   |
| - The hemophilias.....                                  | 22   |
| - Clinical presentation of hemophilia.....              | 27   |
| - Laboratory diagnosis.....                             | 35   |
| - Complications .....                                   | 39   |
| - Immunologic aspect of hemophilia.....                 | 45   |
| . Acquired inhibitors in hemophilia A .....             | 45   |
| . Acquired inhibitors in hemophilia B.....              | 47   |
| . Other specific inhibitors of coagulation .....        | 48   |
| . Acquired immune deficiency syndrom .....              | 52   |
| - Managment.....                                        | 56   |
| - Other congenital coagulation factors deficiency ..... | 59   |
| - Acquired coagulation factor deficiencies.....         | 72   |
| - Coagulation disorders due to platelet destruc-        | 77   |
| tion                                                    |      |
| - ITP .....                                             |      |
| . Humoral and cell-mediated immunity in ITP .....       | 77   |

|                                                                                       | Page |
|---------------------------------------------------------------------------------------|------|
| - Drug induced immune thrombocytopenia.....                                           | 83   |
| - Post transfusion purpura.....                                                       | 85   |
| - Neonatal immune thrombocytopenia.....                                               | 86   |
| - Bleeding disorders caused by vascular abnormalities: Autoimmune vascular purpura... | 88   |
| - Allergic purpura                                                                    | 88   |
| - Summary.....                                                                        | 90   |
| - References.....                                                                     | 92   |
| - Arabic summary.                                                                     |      |

# **INTRODUCTION**

## Introduction

-----

Coagulation disorders are classified into three groups: Coagulation disorders due to deficiency of the coagulation factors, due to platelet destruction or due to the vascular abnormalitis. The immunological aspect in these disorders are helpful in the managment of such cases. In cases of hemophilia the detection of factor VIII inhibitors are helpful in managed <sup>most of</sup> such cases. The immunological study is helpful in diagnosis, management and prevention of different disease. In ITP detection of IgG and IgA are essential to know the type of ITP and for proper managment of such cases.

X

## **AIM OF THE WORK**

## Aim of the work

The aim of this review is to classify and discuss the different types of coagulation disorders. The study of the immunological aspect of the coagulation disorders are helpful in proper diagnosis as in case of ITP and proper management e.g. proper management of hemophilic patients with inhibitors specific to factor VIII.

# **BLOOD COAGULATION**

## Blood coagulation

The hemostatic process has three major components:

- 1- Integrity of the vascular wall and reaction of the blood vessels to injury.
- 2- Platelet activity, and
- 3- Coagulation of the blood (Philip, . . 1980).

### Nomenclature of blood coagulation factors :

The problems of nomenclature have been partially solved by the development of an international standard nomenclature (Macfarlane, 1976).

Table (1) gives this recommended nomenclature.

### Coagulation mechanism<sup>15</sup> divided into three phases: X

phase I deals with the formation of prothrombin activators and can be further subdivided into the intrinsic and extrinsic clotting systems. Phase 2 involves the cleavage of prothrombin into intermediates, one of which is thrombin. During phase 3 fibrinogen is converted to fibrin, and the clot is stabilized.

Table (1) Nomenclature and Synonyms for Coagulation Factors

| <i>Roman<br/>Numeral</i> | <i>Preferred<br/>Descriptive<br/>Name</i> | <i>Synonyms</i>                                                                                                                                 |
|--------------------------|-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| I                        | Fibrinogen                                |                                                                                                                                                 |
| II                       | Prothrombin                               |                                                                                                                                                 |
| III                      | Tissue factor                             | Thromboplastin                                                                                                                                  |
| IV                       | Calcium ions                              |                                                                                                                                                 |
| V                        | Proaccelerin                              | Labile factor, accelerator globulin (AcG), thrombogen                                                                                           |
| VII                      | Proconvertin                              | Stable factor, serum prothrombin conversion accelerator (SPCA)                                                                                  |
| VIII                     | Antihemophilic factor (AHF)               | Antihemophilic globulin (AHG), antihemophilic factor A, platelet cofactor 1, thromboplastinogen                                                 |
| IX                       | Plasma thromboplastin component (PTC)     | Christmas factor, antihemophilic factor B, autoprothrombin II, platelet cofactor 2                                                              |
| X                        | Stuart factor                             | Prower factor, autoprothrombin III, thrombokinase                                                                                               |
| XI                       | Plasma thromboplastin antecedent (PTA)    | Antihemophilic factor C                                                                                                                         |
| XII                      | Hageman factor                            | Glass factor, contact factor                                                                                                                    |
| XIII                     | Fibrin stabilizing factor (FSF)           | Laki-Lorand factor (LLF), fibrinase, plasma transglutaminase, fibrinolyase                                                                      |
| —                        | Prekallikrein                             | Fletcher factor                                                                                                                                 |
| —                        | HMW Kininogen                             | High molecular weight kininogen, contact activation cofactor, Fitzgerald factor, Williams factor, Fleury factor, Reid factor, Washington factor |

(Wintrobe et al., 1981)

### Phase I: Intrinsic clotting system

The intrinsic system is responsible for the formation of a clot in plasma from which all tissue juices are excluded and from which blood cells other than platelets are removed. It involves factors XII, XI, X, IX, VIII, and V, platelet factor 3 and calcium. Clotting via the intrinsic system begins when factor XII is activated by contact with a foreign surface (Wilner et al., 1968). Factor XII a functions to activate factor XI. Neither activation of XII nor activation of XI requires calcium (James, 1975).

The next step in the intrinsic system is the activation of factor IX by the enzyme XIa, this reaction requires calcium, and IXa is a potent coagulant. The next reaction is a complicated one involving factor IX a, factor VIII, calcium, and the phospholipid derived from platelets, platelet factor 3 (Davie et al., 1969). The IX a - VIII - phospholipid complex activates factor X which in turn participates in the conversion of prothrombin to thrombin (Borton et al., 1967). Factor X a is the enzyme that is responsible for the cleavage of prothrombin and factor V and phospholipid only accelerate this reaction (Jobin and Esnouf, 1967).